ClinicalTrials.gg
RecruitingNCT07342972MESK-2Updated Nov 18, 2026

Gastrointestinal Symptoms and Tolerance in Infants Fed Goat or Cow's Milk-based Infant Formula

An interventional study of Goat milk-based infant formula and Cow's milk-based infant formula in Gastrointestinal Tolerance, Gastrointestinal Symptoms and Infections, sponsored by Ausnutria Hyproca B.V.. Recruiting at 1 site in Saudi Arabia. Open to participants aged 14 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ausnutria Hyproca B.V. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
14 Days to 90 Days
Sex
All
01

Study summary

This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow's milk formula on gastrointestinal symptoms and tolerance, and infections in infants.

02

Conditions studied

  • Gastrointestinal Tolerance
  • Gastrointestinal Symptoms
  • Infections
  • Quality of Life
  • Anthropometrics

Browse trials for

Keywords

  • Formula
  • Infant
  • Goat milk-based infant formula
  • RCT
  • Gastrointestinal symptoms
  • Gastrointestinal tolerance
03

In context

Infections

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's planned enrollment of 144 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Ausnutria Hyproca B.V. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Days to 90 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 14 days and 90 days.
  • Healthy singleton term infants born between 37 weeks and 42 weeks of gestation.
  • Infants who have received CMF for at least 7 consecutive days.
  • Exclusive formula feeding.
  • Cow's Milk-related Symptoms Score (CoMiSS®) value at baseline of ≥6 and \<10.
  • Parents' or caregivers, aged ≥18 years, willing to give and adhere to study protocol

Exclusion criteria

Exclusion Criteria:

  • Exclusively or partially feeding with human milk
  • Introduced to solid food, supplementary feeding, use of pre- and/or probiotics as a supplement
  • Congenital or recurrent chronic conditions and/or malabsorption that could interfere with study parameters.
  • Diagnosed cow's milk allergy (CMA) or suspected to have CMA, soy allergy, fish allergy, egg allergy and/or lactose intolerance.
  • Receiving medication (on own initiative or prescription) with regard to FGID (i.e. reflux medication)
  • Sibling already participating in this study
  • Participation in another clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Goat milk-based infant formula

    Other: Goat milk-based infant formula

  • Active comparator
    Control group

    Cow's milk-based infant formula

    Other: Cow's milk-based infant formula

Interventions

  • OtherGoat milk-based infant formula

    Study product is administered on demand until the age of 6 months.

  • OtherCow's milk-based infant formula

    Study product is administered on demand until the age of 6 months.

06

What researchers measure

Primary outcomes

  1. Gastrointestinal symptoms as determined by CoMiSS

    The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).

    Time frame: Difference between groups at Day 14 of the intervention

  2. Gastrointestinal tolerance as determined by IGSQ

    The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.

    Time frame: Difference between groups at the end of the intervention at 24 weeks

Secondary outcomes

  1. Gastrointestinal symptoms throughout the study as determined by CoMiSS

    The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).

    Time frame: From enrollment to the end of the intervention at 24 weeks

  2. Gastrointestinal tolerance throughout the study as determined by IGSQ

    The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  3. Occurrence, duration and severity of gastrointestinal infections as determined by Vesikari

    The Vesikari Clinical Severity Scoring System includes a e-diary card completed by parents, to identify rotavirus gastroenteritis episodes. The Vesikari Clinical Severity Scoring System Parameters score ranges from 0 to 20 with score \<7 as mild symptoms and score 10 to 20 as severe symptoms.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  4. Occurrence, duration and severity of respiratory infections as determined by CARIFS

    Canadian Acute Respiratory Illness and Flu Scale is a validated parental questionnaire, to measure the disease severity of children with acute respiratory illness (ARI) including influenza. CARIFS consists of 18 items covering three domains; symptoms (e.g., cough); function (e.g., play), and parental impact (e.g., clinginess). Each item is scored 0 to 3, with higher scores indicating greater severity of illness. The full scale ranges from 0 to 58. For children older than 5 years the full scale is used; for children younger than 5 years, 3 items (headache, sore throat, and muscle aches) are not used for assessment.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  5. Occurrence, duration and severity of ear infections as determined by AOM-SOS V5

    The Acute Otitis Media Symptom Severity scale (AOM-SOS) Version 5.0 is psychometric scale used to measure the severity of symptoms in children with acute otitis media and has been validated for parent-reported use. A 6-point Likert scale ranging from 'No' to 'An extreme amount' is used to rate the presence of 5 symptoms related to acute otitis media over the preceding 24 hours. The AOM-SOS Version 5.0 total score is obtained by summing the scores on these 5 equally-weighted questions.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  6. Quality of life as determined by PedsQL

    The Pediatric Quality of Life Inventory (PedsQL™) Infant Scales™ is a specific module of the PedsQL™. The objective of this validated questionnaire is to measure generic health-related quality of life in infants. Applicable for infants with acute and chronic health conditions and healthy infants. The questionnaire is composed of 36 items comprising 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning. Higher scores means better HRQOL and fewer problems or symptoms. A 5-point Likert scale from is applied: 0 (Never) to 4 (Almost always). Scores are transformed on a scale from 0 to 100.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  7. Quality of life as determined by WHOQoL-BREF

    The World Health Organization Quality of Life Questionnaire BREF (WHOQoL-BREF) is the shortened version of the WHOQoL-100. The WHOQoL-BREF measures quality of life within the context of an individual's culture, value systems, personal goals, standards of concerns. The measuring instrument consists of 26 items. The raw scoreis transformed to a 0-100 scale, where higher scores indicate higher perceived quality of life.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  8. Weight

    Weight will be measured in kilograms.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  9. Height

    Height will be measured in centimeters.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  10. Head circumference

    Head circumference will be measured in centimeters.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  11. WHO z-scores

    Subject's weight, length and head circumference will be used to calculate the WHO z-scores for weight-for-age, length-for-age, head circumference-for-age, weight-for-length.

    Time frame: From enrollment to the end of the intervention at 24 weeks

  12. Fecal parameters

    The major fecal bacterial groups are defined using 16S RNA sequencing. Further fecal parameters (e.g. pH, SCFA, sIgA, A1AT) are determined with standard laboratory techniques.

    Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24

  13. Sleep and Crying episodes

    Sleep and crying episodes and duration are recorded for 24 hours prior to the visits in diaries.

    Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24

  14. Stool frequency & consistenty

    Stool frequency and consistency are recorded for 24 hours prior to visits in diaries.

    Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24

07

Study locations

1 of 1 sites recruiting
  • King Faissal Specialist Hospital & Research Centre
    Riyadh, Saudi Arabia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.

Of 308 interventional studies with no phase under Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 48. This study's planned 13 months is below that.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Aug 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 15, 2026
StartActual
Aug 26, 2026was Feb 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
King Faissal Specialist Hospital & Research Centre is now Recruiting
Nov 18, 2026
Start date
Feb 2026→Aug 26, 2026 (actual)
Nov 18, 2026
Contact
Study contact's phone or email changed: n•••@ausnutria.nl→c•••@ausnutria.nl. See the current contact
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    King Faissal Specialist Hospital & Research Centre is now Recruiting
    Start date Feb 2026→Aug 26, 2026 (now actual)
    Contact Study contact's phone or email changed: n•••@ausnutria.nl→c•••@ausnutria.nl. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07342972
Lead sponsor
Ausnutria Hyproca B.V.
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Aug 26, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jildou Visser, BSc
Contact
clinicaltrials@ausnutria.nl
+31885015283

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion